Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector5659710.17816/1028-9984-2021-26-1-5-12Original Study ArticlesОригинальные исследованияResearch ArticleMolecular biological characteristics of tumors and results of breast cancer treatment in malesМолекулярно-биологическая характеристика опухолей и результаты лечения рака молочной железы у мужчинhttps://orcid.org/0000-0002-6758-48006663-3600ZyuzyukinaAlena V.ЗюзюкинаАлена Владимировна
Russian Federation
alena-vz@mail.ruhttps://orcid.org/0000-0002-3787-31262097-0304SlepovEvgeniy V.СлеповЕвгений Владимирович
Russian Federation

MD, Cand. Sci. (Biol.)

канд. биол. наук

slepov99@mail.ruhttps://orcid.org/0000-0002-8995-28625070-8140VinnikYury S.ВинникЮрий Семенович
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н, проф.

yuvinnik@yandex.ruhttps://orcid.org/0000-0002-7210-30203632-8415ZukovRuslan A.ЗуковРуслан Александрович
Russian Federation
zukov.ra@krasgmu.ruKrasnoyarsk State Medical University named after Professor V.F. Voyno-YasenetskyКрасноярский государственный медицинский университет им. проф. В.Ф. Войно-ЯсенецкогоKrasnoyarsk Regional Clinical Oncology Center named after A.I. KryzhanovskyКрасноярский краевой клинический онкологический диспансер имени А.И. Крыжановского150120212615121901202110122021Copyright ©; 2021, Eco-VectorCopyright ©; 2021, ООО "Эко-Вектор"2021Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-nd/4.0https://rjonco.com/1028-9984/article/view/56597

BACKGROUND: Male breast cancer is considered a rare condition – less than 1% of all breast cancer cases. 1607 cases of breast cancer were diagnosed by 2019 in Krasnoyarsk region and only 5 cases (0,31%) of the disease were in male patients.

AIM: This study aims to conduct a retrospective analysis of cases of breast cancer treatment in males in the Krasnoyarsk Territory for the period 1998–2019, as well as to assess overall and progression-free survival rates in this category of patients.

MATERIALS AND METHODS: A total of 28 males with diagnosed breast cancer received treatment at the Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky in the period from 1998 to 2019.

RESULTS: Since 2013, an increase in breast cancer in males is noted in the Krasnoyarsk Territory. Average age of the patients at the time of diagnosis was 60.3±10.3 (range – 35 to 83 years). Allocating patients to the clinical stages: 8 patients (28.6%) were diagnosed with stage I of the tumor process, stage II was revealed in 12 (42.9%) patients, stage III was diagnosed in 7 (24.9%) patients and in 1 case (3.6%) cancer was found in situ. Metastatic lesions of the lymph nodes were revealed in 11 patients (39.3%): N1 – 9 patients (81.8%), N2 – 1 patient (9.1%), N3 – 1 patient (9.1%). Luminal A subtype was diagnosed in 3 patients (13.6%), luminal B (HER2-negative) – in 16 patients (72.8%), luminal B (HER2-positive) – in 2 patients (9.1%). 75% of patients received adjuvant therapy. As a result of the treatment, stabilization of the process was registered in 64.3% of cases. 4 patients (14.3%) suffered from recurrence of the disease; 2 patients (7.1%) were diagnosed with multiple primary cancer. For the entire observation period, fatal cases composed 4 (14.3%). Analysis of the overall survival rates for the male patients with breast cancer demonstrated a positive effect of endocrine therapy.

CONCLUSION: The results obtained indicate an increase in the incidence of breast cancer in men in the Krasnoyarsk Territory. Men have the tumor which is hormone-positive and administration of hormone therapy in the adjuvant mode increases overall survival rates.

Обоснование. Рак молочной железы у мужчин относится к редким формам – менее 1% от числа всех опухолей молочной железы. К 2019 г. в Красноярском крае диагностировано 1607 случаев злокачественных новообразований молочной железы и всего 5 случаев (0,31%) приходится на долю мужчин.

Цель. Провести ретроспективный анализ случаев лечения рака молочной железы (РМЖ) у мужчин в Красноярском крае за период 1998–2019 гг., а также оценить показатели общей и беспрогрессивной выживаемости у данной категории пациентов.

Материалы и методы. 28 мужчин с диагнозом «Рак молочной железы», проходившие лечение в Красноярском краевом клиническом онкологическом диспансере им. А.И. Крыжановского в период с 1998 по 2019 г.

Результаты. Начиная с 2013 г. наблюдается рост РМЖ у мужчин на территории Красноярского края. Средний возраст больных на момент установления диагноза составил 60,3±10,3 (диапазон от 35 до 83 лет). Распределение больных по стадиям: у 8 (28,6%) пациентов выявлена I стадия опухолевого процесса, у 12 (42,9%) – II стадия, III – у 7 (24,9%), в 1 (3,6%) случае выставлен рак in situ. У 11 (39,3%) больных выявлено метастатическое поражение лимфатических узлов: N1 – 9 (81,8%), N2 – 1 (9,1%), N3 – 1 (9,1%). Люминальный А подтип диагностирован у 3 (13,6%), люминальный В (HER2-негативный) – у 16 (72,8%), Люминальный В (HER2-позитивный) – у 2 (9,1%). Адъювантную терапию получали 75% больных. На фоне проводимого лечения стабилизация процесса зарегистрирована в 64,3% случаев. Рецидив заболевания выявлен у 4 (14,3%) пациентов, у 2 (7,1%) больных диагностирован первично-множественный рак. 4 (14,3%) летальных случая за весь период наблюдения. Анализ общей выживаемости пациентов мужского пола с РМЖ продемонстрировал положительное влияние проводимой эндокринотерапии на показатели дожития этих пациентов.

Заключение. Полученные результаты свидетельствуют о росте заболеваемости РМЖ у мужчин на территории Красноярского края. У мужчин опухоль является гормонпозитивной, и назначение гормонотерапии в адъювантном режиме увеличивает показатели общей выживаемости.

male breast cancerretrospective analysisoverall survivalendocrine therapyрак молочной железы у мужчинретроспективный анализобщая выживаемостьэндокринотерапияИсследование не имело спонсорской поддержкиCardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(10):1674. doi: 10.1093/annonc/mdz189Cardoso F., Kyriakides S., Ohno S., et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. 2019. Vol. 30, N 10. P. 1674. doi: 10.1093/annonc/mdz189Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2018. Vol. 68, N 6. P. 394–424. doi: 10.3322/caac.21492Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 2013;24(6):1434–1443. doi: 10.1093/annonc/mdt025Ruddy K.J., Winer E.P. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship // Ann Oncol. 2013. Vol. 24, N 6. P. 1434–1443. doi: 10.1093/annonc/mdt025Brinton LA, Carreon JD, Gierach GL, et al. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat. 2010;119(1):185–192. doi: 10.1007/s10549-009-0379-0Brinton L.A., Carreon J.D., Gierach G.L., et al. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database // Breast Cancer Res Treat. 2010. Vol. 119, N 1. P. 185–192. doi: 10.1007/s10549-009-0379-0Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114–2122. doi: 10.1200/JCO.2009.25.5729Korde L.A., Zujewski J.A., Kamin L., et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations // J Clin Oncol. 2010. Vol. 28, N 12. P. 2114–2122. doi: 10.1200/JCO.2009.25.5729Abrahams HJG, Knoop H, Schreurs M, et al. Moderators of the effect of psychosocial interventions on fatigue in women with breast cancer and men with prostate cancer: Individual patient data meta-analyses. Psychooncology. 2020;29(11):1772–1785. doi: 10.1002/pon.5522Abrahams H.J.G., Knoop H., Schreurs M., et al. Moderators of the effect of psychosocial interventions on fatigue in women with breast cancer and men with prostate cancer: Individual patient data meta-analyses // Psychooncology. 2020. Vol. 29, N 11. P. 1772–1785. doi: 10.1002/pon.5522Keinan-Boker L, Levine H, Leiba A, et al. Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men. Int J Cancer. 2018;142(5):910–918. doi: 10.1002/ijc.31121Keinan-Boker L., Levine H., Leiba A., et al. Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men // Int J Cancer. 2018. Vol. 142, N 5. P. 910–918. doi: 10.1002/ijc.31121Massarweh SA, Sledge GW, Miller DP, et al. Molecular Characterization and Mortality From Breast Cancer in Men. J Clin Oncol. 2018;36(14):1396–1404. doi: 10.1200/JCO.2017.76.8861Massarweh S.A., Sledge G.W., Miller D.P., et al. Molecular Characterization and Mortality From Breast Cancer in Men // J Clin Oncol. 2018. Vol. 36, N 14. P. 1396–1404. doi: 10.1200/JCO.2017.76.8861Tynes T, Andersen A. Electromagnetic fields and male breast cancer. Lancet. 1990;336(8730):1596. doi: 10.1016/0140-6736(90)93387-5Tynes T., Andersen A. Electromagnetic fields and male breast cancer // Lancet. 1990. Vol. 336, N 8730. P. 1596. doi: 10.1016/0140-6736(90)93387-5Rosenbaum PF, Vena JE, Zielezny MA, Michalek AM. Occupational exposures associated with male breast cancer. Am J Epidemiol. 1994;139(1):30–36. doi: 10.1093/oxfordjournals.aje.a116932Rosenbaum P.F., Vena J.E., Zielezny M.A., Michalek A.M. Occupational exposures associated with male breast cancer // Am J Epidemiol. 1994. Vol. 139, N 1. P. 30–36. doi: 10.1093/oxfordjournals.aje.a116932Hoffman A, Ben Ishay O, Horesh N, et al. Breast Cancer in Men: A Single Center Experience Over a Period of 22 years. Isr Med Assoc J. 2020;22(3):160–163.Hoffman A., Ben Ishay O., Horesh N., et al. Breast Cancer in Men: A Single Center Experience Over a Period of 22 years // Isr Med Assoc J. 2020. Vol. 22, N 3. P. 160–163.Pan H, Zhang K, Wang M, et al. The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population-based observational study. Cancer. 2020;126 Suppl 16:3830–3836. doi: 10.1002/cncr.32829Pan H., Zhang K., Wang M., et al. The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population-based observational study // Cancer. 2020. Vol. 126 Suppl 16, N. P. 3830–3836. doi: 10.1002/cncr.32829Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405–417. doi: 10.1093/annonc/mdx651Cardoso F., Bartlett J.M.S., Slaets L., et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program // Ann Oncol. 2018. Vol. 29, N 2. P. 405–417. doi: 10.1093/annonc/mdx651Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother. 2007;8(2):193–202. doi: 10.1517/14656566.8.2.193Cutuli B. Strategies in treating male breast cancer // Expert Opin Pharmacother. 2007. Vol. 8, N 2. P. 193–202. doi: 10.1517/14656566.8.2.193